RIQAS (Randox International Quality Assessment Scheme) have recently launched Four New Serology EQA Programs for HIV/Hepatitis, ToRCH, Epstein Barr Virus (EBV) and Syphilis. Each programme covers a wide range of infectious diseases allowing for increased consolidation and cost effectiveness. All samples are made from 100% human plasma and are liquid stable for ease of use and convenience.

4 New Programs

Serology (HIV-Hepatitis) Program Anti-HIV-1, Anti-HIV-2, Anti-HIV-1&2 Combi, Anti-HCV, Anti-HBc, HBsAg, Anti-HTLV-I, Anti-HTLV-II, Anti-HTLV-1&2 Combi, Anti-CMV.

Serology (ToRCH) Program Anti-Toxoplasma IgG, Anti-Toxoplasma IgM, Anti-Rubella IgG, Anti-Rubella IgM, Anti-CMV IgG, Anti-CMV IgM, Anti-HSV1 IgG, Anti-HSV1 IgM, Anti-HSV2 IgG, Anti-HSV2 IgM, Anti-HSV-1&2 IgG Combi, Anti-HSV-1&2 IgM Combi

Serology (Epstein Barr Virus) Program Anti-EBV VCA IgG, Anti-EBNA IgG, Anti-EBV VCA IgM.

Serology (Syphilis) Program Suitable for RPR, VDRL and TPHA methods.

RIQAS is the largest international EQA scheme in the world with over 22,000 participants in more than 100 countries.

RIQAS Key Benefits
• High quality samples
• Flexible programme options
• Sophisticated yet easy to interpret reports provided within 24-48 hours
• Accreditation to a number of internationally recognised standards including ILAC G13:2007 (ISO/IEC 17043) and ISO13485
• Unrivalled technical support via our team of RIQAS scientists and experts